DePuy’s parent company won approval today from the European Union of its $21.3 billion purchase of Synthes Inc.
The deal was approved after DePuy recently sold its trauma unit to Biomet.
The European Commission said in an e-mailed statement today that the deal elminated antitrust concerns.
“We obtained remedies to ensure that competition will remain strong in these markets, for the ultimate benefit of patients and social security systems,” said EU Competition Commissioner Joaquin Almunia in the statement.
Johnson and Johnson, the parent company of DePuy, offered to buy Synthes in April 2011.
The European regulator began a probe in Novemeber to look at the deal.
DePuy is still looking for approval from U.S. regulators but now has the approval of the European Union, Japan, Canada and China.
A Johnson & Johnson spokesperson said the deal is expected to close by the end of June.
The offer from Biomet to purchase DePuy’s trauma unit for $280 million expires June 1.
